What question did this study set out to answer?

To compare the efficacy and safety of once-daily valganciclovir against oral ganciclovir three times daily for cytomegalovirus (CMV) prevention in high-risk donor-seropositive, recipient-seronegative solid organ transplant recipients.

April 1, 2004American Journal of TransplantationOpen Access

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

View Full Paper

Ask AI

Bookmark

Authors

CPCarlos V. PayáTufts University AHAtul HumarUniversity Health Network EDEd DominguezMethodist Dallas Medical Center

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates equivalent prevention of cytomegalovirus disease with once-daily valganciclovir in organ recipients, suggesting a more convenient prophylactic regimen.

Key Points

To compare the efficacy and safety of once-daily valganciclovir against oral ganciclovir three times daily for cytomegalovirus (CMV) prevention in high-risk donor-seropositive, recipient-seronegative solid organ transplant recipients.
Randomized, prospective, double-blind, double-dummy trial enrolling 364 CMV D+/R- solid organ transplant recipients.
Interventions comprised valganciclovir 900 mg once daily versus oral ganciclovir 1000 mg three times daily initiated within 10 days post-transplant and continued through day 100, with clinical follow-up at 6 and 12 months.
Endpoint committee-defined CMV disease occurred in 12.1% of valganciclovir recipients versus 15.2% of ganciclovir recipients at 6 months, and in 17.2% versus 18.4% by 12 months.
CMV viremia during prophylaxis was significantly lower with valganciclovir than ganciclovir (2.9% vs. 10.4%, p=0.001), reaching 48.5% versus 48.8% respectively by 12 months.
Adverse event rates were similar between groups, with the exception of a higher incidence of neutropenia in the valganciclovir arm (8.2% vs. 3.2%).

Cite This Study

Payá et al. (2004) studied this question.

synapsesocial.com/papers/6aa6bee724014aaf7fdd6627 https://doi.org/10.1111/j.1600-6143.2004.00382.x

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates equivalent prevention of cytomegalovirus disease with once-daily valganciclovir in organ recipients, suggesting a more convenient prophylactic regimen.

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider